1. Context {#sec69579}
==========

1.1. Cleft Palate Development Scenario {#sec69578}
--------------------------------------

Palate is a structure that separates oral and nasal cavities from each other. Palatogenesis happens during weeks 8-12 in human intrauterine life (embryonic days E12-E15 in mice). The palate gets divided into primary and secondary palates. During palatogenesis, fusion of two maxillary outgrowths, named palatal shelves, forms the majority of palate. These shelves appear as protrusions on the lateral walls of the oronasal cavity, growing vertically and downward around the tongue. After a while, the palatal shelves elevate to a horizontal position and fuse on midline above the tongue to form the palate ([Figure 1](#fig13472){ref-type="fig"}) ([@A15393R1]).

![Palatal Shelves Grow Vertically and Downward First, After a While They Turn Upward and Fuse in Midline, Above the Tongue, to Separate Oral and Nasal Cavities.](ircmj-16-09-15393-g001){#fig13472}

Interruption in the palatogenesis process for any reason may lead to cleft palate (CP) which is characterized by a defect in oronasal separation. This malformation is a very frequent congenital defect in human and it may or may not be accompanied by cleft lip (CL) ([@A15393R2]). Khazaei et al. reported 1.0 CP along with CL (CPL) per 1000 live births in Iran, which is lower compared to other countries ([@A15393R3]). Both genetic and environmental factors could have roles in orofacial clefts, CP and/or CL incidence. Many genes and signaling pathways are involved in palatogenesis, impaired action of each could lead to orofacial clefts; further information presented in [Table 1](#tbl17723){ref-type="table"}. Genes can be categorized into four groups:

1.  Genes expressed in a particular area or period of palate development;

2.  Genes with biological activities without direct involvements, like receptors for retinoic acid and folic acid;

3.  Homeobox genes which determine the identity of embryonic regions along the anterior-posterior axis;

4.  Genes involved in deactivation and excretion of xenobiotics as those in P-450 cytochrome system ([@A15393R4]).

Environmental factors like folic acid deficiency ([@A15393R4]), toxins in the living area ([@A15393R5]), teratogens such as phenytoin ([@A15393R6]), corticosteroids and retinoic acid ([@A15393R7]), and also consanguinity ([@A15393R5]) may affect the gene expression pattern and cause CP and/or CL. Further research is required toward understanding the exact molecular events.

###### Some Genes Incorporating in Palatogenesis and Cleft Palate and/or Cleft Lip Formation ^[a](#fn14671){ref-type="table-fn"}^

  Gene                                      Mechanism of CP and/or CL Formation                                                                                                                                                                                                                Reference
  ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  **Bmp signaling**                         Disruption of type I Bmp receptor in the maxillary mesenchyme and throughout the oral epithelium resulted in CL and CP.                                                                                                                            ([@A15393R8], [@A15393R9])
  **PDGF signaling**                        PDGF and its receptors had specific roles in promoting tissue-tissue interactions to control cell migration and proliferation. Some deletions in this group resulted in CP.                                                                        ([@A15393R10])
  **Wnt signaling**                         Expression of multiple Wnts was essential for fusion of facial prominences. Onset of the cleft was linked to disruptions in various Wnt genes.                                                                                                     ([@A15393R11])
  **TGFβ3**                                 TGFβ3 is expressed by epithelial cells of medial edge in palatal shelves just prior to fusion of them; it probably regulates the breakdown of epithelia which lie between the palatal shelves. If TGFβ3 did not expressed CP would be developed.   ([@A15393R12])
  **FOXE1**                                 FOXE1 was expressed in the secondary palate epithelium. mice with a null mutation in FOXE1 had CP.                                                                                                                                                 ([@A15393R13])
  **VAX1**                                  Single nucleotide polymorphisms in VAX1 was overrepresented in patients with CL and CP, making variants in VAX1 strong candidates for etiopathogenesis of CL and CP. Mouse Vax1 knockouts showed CP.                                               ([@A15393R14])
  **Noggin**                                Loss of noggin function resulted in apoptosis in the palatal epithelium and reduced cell proliferation of the anterior palatal mesenchyme, resulting in CP in the anterior region.                                                                 ([@A15393R15])
  **Genes encoding Adamts9 and Adamts20**   Simultaneous disruption of these genes resulted in CP with defects in early outgrowth, elevation and approximation of the palatal shelves.                                                                                                         ([@A15393R16])
  **Msx1**                                  Lacking Msx1 exhibited specific cell proliferation defects in the anterior region, resulting in CP in those regions.                                                                                                                               ([@A15393R17])
  **Mn1**                                   Lacking Mn1 showed growth deficits in the middle and posterior regions of the palatal shelves, resulting in CP in these regions.                                                                                                                   ([@A15393R18])
  **Shox2**                                 Lacking Shox2 exhibited a cleft within the anterior palate.                                                                                                                                                                                        ([@A15393R19])
  **Tbx22**                                 Lacking Tbx22 displayed cleft palate, with the severity varying from a complete CP to submucous CP, as a result of difficulties in palatal shelves elevation.                                                                                      ([@A15393R20])
  **Osr1 and Osr2**                         These genes encoded zinc-finger transcription factors; they targeted disruption of Osr2, causing cell proliferation reduction in the medial side of the developing palatal shelves and with disrupted mediolateral patterning.                     ([@A15393R21])
  **Fgfr2**                                 A targeted point mutation in Fgfr2 led to ligand-independent activation of the receptor, resulting in increased palatal shelf mesenchyme proliferation in the lateral half of the shelf and delayed elevation, leading to CP.                      ([@A15393R22])

^a^Abbreviations: BMP, bone morphogenic protein; CP, cleft palate; CL, cleft lip; PDGF, platelet-derived growth factor; Wnt, wingless type; TGFβ3, transforming growth factor ; FOXE1, forkhead box protein E1; VAX1, Ventral anterior homeobox 1; MSX1, Msh homeobox 1; SHOX2, Short stature homeobox 2; TBX22, T-box transcription factor; OSR1, Odd-Skipped-Related 1; OSR2, Odd-Skipped-Related 2; FGFR2, Fibroblast growth factor receptor 2.

2. Evidence Acquisition {#sec69587}
=======================

PubMed search was undertaken using search terms including \'cleft palate repair\', \'palatal cleft closure\', \' cleft palate + stem cells\', \'cleft palate + plasma-rich platelet\', \'cleft palate + scaffold\', \'palatal tissue engineering\', and \'bone tissue engineering\'. The found articles were included if they defined a therapeutic strategy and/or assessed a new technique. We tried to gather the newest articles about cleft palate repair.

2.1. Current Therapeutic Strategies {#sec69580}
-----------------------------------

The ability to speak and feed normally is the essential goal of CP treatment. In addition, the treatment procedure should consider the normal facial appearance. Patients with CP, CL or both (CPL), often require long extensive treatments which may cause financial burden, morbidity and other medical complications ([@A15393R23]). LeMonnier presented the first surgical CP repair. He incised the cleft edges and placed sutures leading to suppuration and then healing across the defect. Later, VonLangenbeck introduced the use of mucoperiosteal flaps to close clefts involving the hard palate ([@A15393R24]). After that, a wide range of surgical techniques has been described to repair clefts, all with relative advantages and disadvantages, and all based on bone grafting ([@A15393R25]). One of the major problems in cleft repair is bony reconstruction of alveolar and hard palate defects. Surgical repair by utilizing autogenous bone grafts is the current standard of care; Tibia, mandible, iliac, cranium and ribs are common donor sites ([@A15393R26]). Bone grafts classified as primary, secondary, and tertiary, are based on the timing of the grafting procedure ([@A15393R26]). This procedure has several disadvantages, mostly related to the donor site; morbidity after the bone graft harvest is the major problem. Complications are seen early and/or late in the donor site which include postoperative pain, wound infection, bleeding, altered sensation, local tissue injury, poor mobility, and possibly of fracture of the donor bone. Late complications include chronic pain, unaesthetic scarring, gait disturbance, and paresthesia ([@A15393R26]). Furthermore, bone graft harvest ultimately yields a very limited quantity of bone. This bone can also be absorbed; thus, full integration into the host site is not achieved ([@A15393R27]). Reports show 41-73% success rate of primary alveolar cleft repair. Unfortunately, patients with persistent alveolar defects require secondary bone grafting ([@A15393R28]). Meyer et al. reported only 82% successful secondary alveolar bone grafting rate after a long-term follow-up cohort study ([@A15393R29]). Moreover, grafted bone needs to be very tenacious to support tooth eruption and to tolerate physical stress from muscles of mastication. To solve the problems of donor site morbidity, investigators have presented allogeneic and synthetic materials for grafting. However, there is still a risk of infection in addition to immune response elicitation and problems with structural integrity ([@A15393R27]). Furthermore, the surgical repair of CPs has some unwanted consequences. Disturbance of facial growth is the common result ([@A15393R30]). Midface retrusion makes other therapies necessary to establish a normal occlusion and improves facial appearance ([@A15393R31]). In addition, postoperative development of an oronasal fistula in the grafted area still remains a significant problem of the palatal reconstruction surgery. Reports have mentioned an incidence ranging from 11% to 23%, with the most likely site being the junction of the hard and soft palates ([@A15393R32]-[@A15393R35]). Depending on size, fistulas may lead to hypernasal speech, nasal regurgitation, and food trapping. Patients with bilateral clefts appeared to have a 2- to 3-fold higher incidence of postoperative fistula development compared with unilateral clefts ([@A15393R36], [@A15393R37]). Another surgical approach for palatal cleft repair is using buccal fat pad applied for treatment of CP less than 20 mm in length, located in the posterior two-thirds of the palate ([@A15393R38]). Buccal fat pad has been used in both primary palatal cleft repair and treatment of postoperative fistula ([@A15393R39]-[@A15393R42]). Use of buccal fat pad may result in a reduction of palatal scarring, which may limit the subsequent maxillary growth disturbance ([@A15393R27]). Fujimura et al. evaluated the utility of combining the pedicled buccal fat covered with lyophilized dermis in adult patients with the successful treatment of oronasal fistula ([@A15393R43]).

2.2. Using Scaffolds for Cleft Palate Repair {#sec69581}
--------------------------------------------

A scaffold provides a solid framework in a desirable site for cell growth, also allowing cell attachment and migration. Surgeons may use an empty scaffold to induce host cell migration, or they may employ it as a carrier for cells in cell therapy ([@A15393R44]). Scaffolds for engineering bone should be biocompatible and should not stimulate the immune reaction. They should also be absorbable and the absorption rate must be almost same as bone formation rate. Moreover, a scaffold should be able to allow bone cells to migrate and proliferate. Finally, it must be physically stable and easy to manufacture and sterilize and should be handy to use. It should allow the cell-cell interaction and diffusion of nutrients and metabolites ([@A15393R45]). Chemical and topographic surface properties of the scaffold can effect cell adhesion, proliferation and migration ([@A15393R46]). Recently, it was shown that the presence of nano-structures in polymer-based composite scaffolds could be more effective for osteoblasts in comparison with micro-structures ([@A15393R47]). Therefore, many materials have usually been used as bone tissue engineering scaffolds; collagen ([@A15393R48], [@A15393R49]), hyaluronic acid ([@A15393R50]), and hydroxyapatite ([@A15393R51], [@A15393R52]) are some common examples. These materials may be used either alone or in combination with other different substances. Recently, mesoporous bioactive glass has been developed as a scaffold with excellent osteogenic properties for bone regeneration ([@A15393R53]). Biodegradation and biocompatibility of novel poly (epsilon-caprolactone)/nano-fluoridated hydroxyapatite (PCL-FHA) scaffolds were investigated as well. The osteoblast-like cells were attached to and proliferated on PCL-FHA ([@A15393R54]). In addition, acellularized dermal matrix (AlloDerm) has been applied for repair of palatal fistulas. AlloDerm can significantly reduce the fistula recurrence rates ([@A15393R55]-[@A15393R57]). Platelet rich fibrin (PRF) has been also examined as a scaffold for human osteoblast carrier. Metabolic activity and proliferation of human osteoblasts were supported to a significantly high extent using PRF membranes, in vitro ([@A15393R49]). Scaffolds are provided in various forms including porous solid meshes, foams, and injectable gel networks. Injectable gels are desirable because they can be applied for irregular shaped defects; they can be utilized in a noninvasive procedure, and just by simple mixing they are combined with therapeutic agents or cells ([@A15393R58]).

2.3. Applying Stem Cells to Engineered Palates {#sec69584}
----------------------------------------------

Tissue engineering is a novel technique which applies stem cells and/or differentiated cells, scaffolds and signaling molecules to achieve clinical therapeutic goals. Characteristics of an optimal cell source include availability in large quantities, no immune rejection, no graft versus host disease, no tumorigenicity, predictable differentiation potential of stem cells, and integration into the surrounding tissues ([@A15393R59]). Embryonic stem cells (ESCs) are a source that may be used in tissue engineering. These cells exhibit long-term proliferation in vitro and the ability to differentiate into any cell type in the human body ([@A15393R44]), but there is a concern about their tumorigenic properties ([@A15393R60]). Mesenchymal stem cells (MSCs) are considered as a suitable choice for bone tissue engineering ([@A15393R61]). There are different sources for MSCs, including umbilical cord blood (UCB-MSCs), Wharton\'s jelly (UC-MSCs), bone marrow (BMMSCs) ([@A15393R61]), and adipose tissue (ADSCs) ([@A15393R62], [@A15393R63]). Autologous BMMSCs possess a high proliferative potential and the ability to differentiate into osteoblastic cells and they can induce bone formation ([@A15393R64], [@A15393R65]). Furthermore, UC-MSCs are an available source of cells for bone tissue engineering and could have broad application prospects in tissue repair ([@A15393R61]). Different kinds of stem cells have been applied for tissue regeneration in CP and alveolar cleft in different studies. Among them, there are experimental and clinical studies which suggested that tissue-engineered bone may provide an acceptable alternative for CP repair ([@A15393R66]).

### 2.3.1. Experimental Studies {#sec69582}

De Kok et al. evaluated MSC-based alveolar bone regeneration in a canine alveolar defect model using both autologous and allogeneic BMMSCs. Cells were loaded onto hydroxyapatite/tricalcium phosphate matrices. allogeneic BMMSCs. Cells were loaded onto hydroxyapatite/tricalcium phosphate matrices. Histomorphometrical analysis showed new bone formed within the pores of the matrices loaded with autogenic BMMSCs or allogenic BMMSCs in equivalent amount. There was histological evidence showing no immunological response to neither autologous nor allogeneic BMMSCs. Analysis of circulating antibody levels against BMMSCs also supported the hypothesis that MSCs did not induce a systemic response by the host. After nine weeks, the labeled cells were present within the lacunae of newly formed bone, proposing that autologous and allogeneic BMMSCs have the capacity to regenerate bone within craniofacial defects ([@A15393R67]). Conejero et al. used osteogenically differentiated rat fat-derived stem cells, seeded onto poly-L-lactic acid scaffold, to repair rat palatal bone defect models. They demonstrated the feasibility of using these cells for healing such defects, and also proved bone formation in the treated area ([@A15393R63]). Kim et al. recruited periodontal ligament stem cells (PDLSCs) and bone marrow stem cells (BMSCs) to regenerate alveolar bone in the dog canine peri-implant defect model. They found these cells effective and BMSCs were more impressive than PDLSCs in bone formation ([@A15393R68]). Ou et al. investigated restoration of the alveolar cleft with engineered bone, constructed by sponge collagen protein combined with autologous BMMSCs, in the dog alveolar cleft model. Twelve weeks after implantation, 3-dimensional CT and histological examination showed acceptable bone formation in the experimental model compared to the control. It was concluded that these materials can restore the defect of alveolar bone effectively and they can be used clinically to treat alveolar cleft ([@A15393R69]). Mylonas et al. compared the efficiency of bioglass and synthetic hydroxyapatite/tricalcium phosphate granular scaffolds loaded by allogeneic BMMSCs for alveolar bone repairmen in a dog model. No difference was shown in the newly formed bone percent area using these scaffolds, although both exhibited desirable results ([@A15393R70]). Recently, Pourebrahim et al. did a survey to compare bone regeneration of tissue engineered bone from canine ADSCs and autogenous bone graft in the bilateral maxillary alveolar cleft model in dog. For osteogenic differentiation of the undifferentiated cells, they were seeded into a hydroxyapatite/beta-tricalcium phosphate scaffold, overwhelmed in specific osteogenic medium for 21 days. This material was applied on one side and corticocancellous tibial autograft was added on the other side. Bone regeneration was evaluated by histomorphometry on days 15 and 60 after implantation. There was a significant difference between the tissue-engineered side and autografted side, with bone autograft superiority ([@A15393R66]).

### 2.3.2. Clinical Studies {#sec69583}

Behnia et al. evaluated the effect of recombinant platelet derived growth factor and in vitro osteogenic differentiated human bone marrow mesenchymal stem cells (hBMMSCs) in the secondary alveoloplasty. They reported significant improvement in bone regeneration three months after the operation, suggesting an enhancement effect of recombinant platelet derived growth factor with hMSCs on regeneration capacity of the cells ([@A15393R71]). Gimbel et al. compared donor site pain in both tissue engineering minimally invasive iliac crest bone graft and traditional iliac crest bone graft techniques for alveolar bone defect repair, to determine if a tissue engineering technique with similar bone healing results offered any decreased morbidity. Their results exhibited closure of alveolar cleft defects with an absorbable collagen sponge and bone marrow stem cells eventuated in reduced donor site morbidity and decreased the donor site pain intensity and frequency ([@A15393R72]). However, bone marrow aspiration is an undeniable part of BMSCs extraction; so, BMSCs application fails to totally obviate the donor site morbidity ([@A15393R73]).

2.4. Synthetic Adjuvant in Engineered Palates {#sec69585}
---------------------------------------------

The BMP signaling molecules family has been used to induce osteoblastic differentiation. The recombination technology now allows production of large, pure quantities of rhBMP-2 which can be used widely in clinics and laboratories. In a proper environment, rhBMP-2 can cause bone formation by inducing stem cells to differentiate into bone forming cells ([@A15393R74]). Mayer et al. evaluated rhBMP-2 in maxillary alveolar clefts in 24 adults, skeletally mature Foxhound dogs. Bilateral clefts were created artificially, 1 cm in bony width. There were three treatment groups: (1) rhBMP-2 combined with the copolymer poly(lactide-co-glycolide) and autogenous blood, (2) poly(lactide-co-glycolide) and autogenous blood, (3) autograft from the posterior iliac crest; and an untreated group as control. Radiographical and histological assessments were performed two and four months after the treatment. The results showed more bone regeneration in the autograft group at two months, but after four months there were no significant differences between this group and the rhBMP-2 group ([@A15393R75]). After that, Chin et al. demonstrated clinically the feasibility of using rhBMP-2 to repair alveolar clefts without the use of autogenous graft tissue. Their results were shown constructed alveolus bone, performed as normal bone clinically. In addition, histological assessment proved that it was a normal and vital bone ([@A15393R76]). Herford et al. examined bony regeneration of premaxillary clefts by using rhBMP-2 within a collagen sponge carrier in clinic. Computed tomographic studies, before and four months after the operation, revealed that such defects can have complete osseous regeneration induced by rhBMP-2 ([@A15393R77]). Nguyen et al. also compared the therapeutic benefits of absorbable collagen sponge, absorbable collagen sponge plus rhBMP-2, hydroxyapatite-tricalcium phosphate scaffold, hydroxyapatite-tricalcium phosphate scaffold plus rhBMP-2, and control group on surgically created defects in rats. Radiomorphometrical and histomorphometrical assessments at four, eight, and 12 weeks showed an increase in bone formation in animals treated with hydroxyapatite-tricalcium phosphate plus rhBMP-2 (P \< 0.05; four weeks) compared with the empty scaffold ([@A15393R28]). Alonso et al. did a survey to compare the effect of a combination of a resorbable collagen matrix along with rhBMP-2 with traditional iliac crest bone graft for closure of alveolar defects. The authors concluded that rhBMP-2 therapy had satisfactory bone healing effects and it could reduce tissue morbidity ([@A15393R78]). Furthermore, a novel technique which encased rhBMP-2 in a demineralized bone matrix scaffold (BMP/DBM) was developed as an alternative to autografting for secondary alveolar cleft reconstruction. Excellent results were achieved clinically ([@A15393R79]). Recently, Woo et al. reported adverse events after the use of rhBMP-2 as an alternative to autogenous bone graft in oral and maxillofacial surgical procedures. They found that 66.3% of patients with reconstruction of mandible after fracture or cancer or alveolar cleft repair by means of rhBMP-2 reported local reactions, graft failure, infections and other wound complications and 30.1% required additional surgery to address the reported adverse events ([@A15393R80]). Such reports make it necessary to use natural materials instead of synthetic ones.

2.5. Platelet-Rich Plasma Usage as a Natural Adjuvant in Engineered Palates {#sec69586}
---------------------------------------------------------------------------

In regenerative medicine, tissue repair is strongly dependent on formation of new blood vessels and capillaries. Platelet-rich plasma (PRP) is a blood product with a high platelet concentration and the rationale beyond using platelets in tissue engineering is the release of bioactive factors which collaborate in tissue regeneration. Platelets contain a number of growth factors such as platelet-derived, vascular endothelial, beta-type transforming, epidermal, fibroblast and insulin-like I, which promote angiogenesis and synthesis of the extracellular matrix ([@A15393R81]-[@A15393R83]). As one of the main components in tissue regeneration, we successfully applied PRP to treat nonhealing wounds ([@A15393R82]), vesicovaginal fistulas ([@A15393R83]), and stress urinary incontinence ([@A15393R81]). In one CP case, we injected autologous PRP which is described in details in the following section. There are a few reports about using PRP into grafts for alveolar clefts treatment as a source of growth factors for osteogenic differentiation. Osteoregeneration efficacy of autologous bone grafting in PRP has been clinically tested by Oyama et al. They reported higher volume ratio of bone regeneration in PRP-applied cases than control cases who did not receive PRP in their treatments. It was suggested that PRP could enhance bone regeneration and may be beneficial in CP and CL patients' treatment procedures ([@A15393R84]). Ouyang et al. evaluated the effect of PRP as an adjunct to bovine porous bone mineral (BPBM) graft in treatment of periodontal intra bony defects clinically. Their results showed a significant favorable clinical improvement in treating such defects by PRP and BPBM application simultaneously ([@A15393R85]). Hibi et al. applied autologous MSCs combined with PRP for an alveolar cleft osteoplasty of a nine-year-old female patient. Results showed promising bone regeneration and bridging of the cleft after six months ([@A15393R86]). Lee et al. designed a longitudinal survey to evaluate the outcomes of secondary autogenous bone graft combined with PRP in the alveolar cleft. The study considered two groups including 35 alveolar clefts in 30 patients with grafted autogenous bone and PRP and 36 clefts in 30 patients with grafted autogenous bone alone. The density and resorption of the grafted bone was assessed at one week, and one, three, six, and 12 months postoperatively. The authors suggested that PRP may improve bone remodeling in the early phase; however, PRP seemed to have no effect on bone resorption following secondary bone graft in long term ([@A15393R87]). Rullo et al. reported a case of alveolar cleft bone grafting along with PRP application. They observed satisfactory results both on bone and soft tissue regeneration ([@A15393R88]). In a clinical study, Luaces-Rey et al. compared alveolar reconstruction in secondary alveoloplasty with or without PRP. They evaluated the treatment results in two groups of patients. In one group, secondary alveoloplasty was performed using autogenous bone graft and in the second group PRP was added to the autogenous bone grafting procedure. Digital orthopantomography was performed immediately after the operation and again three and six months later. In contrast to the previous study, the data showed no significant differences between the two groups regarding bone regeneration amount ([@A15393R89]). However, Marukawa et al. obtained more favorable results in a similar study. There was a significant reduction in postoperative bone resorption, particularly in the PRP group ([@A15393R90]).

3. Results {#sec69588}
==========

In this mini-review, we reported a summary of the key points concerning cleft palate development, genes involving this defect, current therapeutic strategies, recently novel aspects, and future advances in treatments for easy and fast understanding of the concepts, rather than a systematic review. In addition, the results have been integrated with our recent experience.

4. Conclusions {#sec69590}
==============

According to the literature review as well as our unpublished experiences, we proposed a novel technique for CP management. On the basis of our hypothesis, a CP treatment could be improved by PRP injection around the defected margins. The injection may be repeated after a while in larger defects. Since we provided a mini-review study, we did not explain all the aspects in details which was the limitation of our study. The strong point of our study was brief and understandable explanations in each part which helped reader find out the whole subject in a short time.

4.1. Case Report {#sec69589}
----------------

In a one-year-old female case, a fistula was developed after bone autografting for CP treatment. The procedure needed to be repeated after 6-12 months. Meanwhile, for increasing the success rate, we suggested to inject hPRP (human Plasma-Rich Platelet) along fistula borders before surgery. Three injections were done at two-month intervals. After the third injection, a reduction was observed in the fistula size. In addition, free margins turned thick and well vascularized; tissue grafting was performed successfully. Unfortunately, another fistula appeared on another site of palate after a while. The patient was a candidate for tissue grafting from tongue or buccal area, an invasive procedure, six months later. We decided to continue less invasive PRP application. Again, three injections were done. Surprisingly, sufficient tissue was generated two months after the third injection and the fistula was closed with no more graft needed. The present experience drove us to the hypothesis that PRP can not only reduce the size of defect, but it can also increase angiogenesis as an important factor for tissue grafting (unfortunately there was no publishable picture available). Furthermore, the surgical interference is still the gold standard treatment procedure for CP, so we strongly recommend our technique for small defects; in wider defects we recommend it before surgery to enhance angiogenesis and reduce graft failure rate.
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